文献速递淋巴瘤

2024年应用MYD88Leu265Pro与IL-10对原发性中枢神经系统淋巴瘤进行分子诊断

Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10.
PubMed 文献 · Lancet Haematol · 2024-01-01

本观点文章讨论原发性中枢神经系统淋巴瘤(PCNSL)早期诊断依赖立体定向活检组织病理诊断,脑脊液或玻璃体液细胞学诊断仅见于罕见情况。作者汇总证据认为,PCR法检测MYD88Leu265Pro热点突变与酶联免疫吸附法检测IL-10可在外周血、血浆、房水、玻璃体液和脑脊液中评估,尤其联合检测时具有较高敏感度和特异度,并列举诊断中常见困难以说明这两种标志物的作用与指征。

要点

  • PCNSL疑似病例需经立体定向活检组织病理确诊,脑脊液或玻璃体液细胞学诊断仅见于罕见情况。
  • 多数脑脊液、房水、玻璃体液和外周血候选分子标志物检测方法尚未标准化、周转时间长、昂贵且实验室间重复性低。
  • MYD88Leu265Pro(PCR法)与IL-10(酶联免疫吸附法)可在多类样本中评估,尤其联合检测时敏感度和特异度较高。

核心结论

  • 作者认为,有证据支持在PCNSL诊断中常规使用MYD88Leu265Pro与IL-10,以提高这一侵袭性肿瘤的及时识别。

研究设计与样本

  • 本文为观点文章(Viewpoint),汇总支持在PCNSL诊断中常规使用MYD88Leu265Pro与IL-10的证据,并列举PCNSL诊断中常见困难的示例。

主要发现

  • 多项独立研究显示,MYD88Leu265Pro与IL-10可在PCNSL患者的外周血、血浆、房水、玻璃体液和脑脊液中便捷评估,具有较高敏感度和特异度,尤其联合检测时。
  • 多数候选分子标志物的检测方法尚未标准化、周转时间长、昂贵,且实验室间重复性低。
  • MYD88Leu265Pro热点突变目前由PCR法检测并可靠用于某些淋巴瘤的诊断,IL-10由酶联免疫吸附法测定并常规用于诊断和监测不同常见代谢与免疫疾病。

临床怎么用

  • 作者认为,有证据支持在PCNSL诊断中常规使用MYD88Leu265Pro与IL-10,尤其联合检测,以改善及时识别。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early diagnosis is crucial for the successful treatment of primary CNS lymphoma (PCNSL), a rapidly progressing tumour. Suspicion raised on brain MRI must be confirmed by a histopathological diagnosis of a tumour specimen collected by stereotactic biopsy. In rare cases, cerebrospinal fluid (CSF) or vitreous humour might aid in providing a cytological diagnosis. Several disease-related, patient-related, and treatment-related factors affect the timing and accuracy of diagnosis and patient outcome. Some molecules detected in CSF, aqueous and vitreous humour, and peripheral blood were proposed as diagnostic biomarkers for PCNSL; however, detection methods for most of these molecules are not yet standardised, have a long turnaround time, are expensive, and have little reproducibility among labs. By contrast, the MYD88Leu265Pro somatic hotspot mutation, revealed by PCR-based assay, is currently and reliably used during the diagnosis of some lymphomas, and IL-10, measured by enzyme-linked immunosorbent assay, is routinely used to diagnose and monitor different common metabolic and immunological diseases. Several independent studies have shown that MYD88Leu265Pro and IL-10 can be easily assessed in peripheral blood, plasma, aqueous and vitreous humour, and CSF of patients with PCNSL with substantial sensitivity and specificity, especially when evaluated in combination. In this Viewpoint, evidence supporting the routine use of MYD88Leu265Pro and IL-10 in diagnosing PCNSL is considered, and some examples of the frequent difficulties found in the diagnosis of PCNSL are provided, highlighting the role and indications of these two biomarkers to improve the timely recognition of this aggressive tumour.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Calimeri T, Anzalone N, Cangi MG, et al. Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10. Lancet Haematol. 2024. PMID: 38937027. doi:10.1016/S2352-3026(24)00104-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。